开发一种编码肿瘤抑制 microRNA 的溶瘤重组水疱性口炎病毒。
Development of an Oncolytic Recombinant Vesicular Stomatitis Virus Encoding a Tumor-suppressor MicroRNA.
机构信息
Department of Orthopaedic Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
Department of Orthopaedic Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
出版信息
Anticancer Res. 2020 Nov;40(11):6319-6325. doi: 10.21873/anticanres.14652.
BACKGROUND
Attempts have been made to enhance systemic therapy for osteosarcoma. In our previous study, the systemic administration of a vesicular stomatitis virus (VSV) improved the survival rates of mice with osteosarcoma but did not improve the long-term survival of the animals.
MATERIALS AND METHODS
In the present study, we developed a novel oncolytic VSV by incorporating tumor-suppressor microRNA143 (rVSV-miR143) to compare the antitumor effects of various doses (10×10, 5×10, and 1×10 multiplicity of infection) of rVSV-miR143 with those of VSV in vitro.
RESULTS
The cytotoxicity and migration-inhibitory effects of rVSV-miR143 on the osteosarcoma cells were significantly higher than those of VSV alone at a dose of 5×10 multiplicity of infection, indicating that rVSV-miRNA143 enhances the antitumor effect at certain doses.
CONCLUSION
VSV incorporating tumor-suppressor miRNA143 demonstrated a synergistic antitumor effect on osteosarcoma cells in vitro.
背景
人们曾尝试增强骨肉瘤的系统治疗。在我们之前的研究中，囊泡性口炎病毒（VSV）的全身给药提高了骨肉瘤小鼠的存活率，但并未提高动物的长期存活率。
材料与方法
在本研究中，我们通过整合肿瘤抑制 microRNA143（rVSV-miR143）开发了一种新型溶瘤 VSV，以比较不同剂量（10×10、5×10 和 1×10 感染复数）的 rVSV-miR143 与 VSV 在体外的抗肿瘤效果。
结果
在 5×10 感染复数时，rVSV-miR143 的细胞毒性和迁移抑制作用明显高于单独的 VSV，表明 rVSV-miRNA143 在一定剂量下增强了抗肿瘤作用。
结论
携带肿瘤抑制 miRNA143 的 VSV 在体外对骨肉瘤细胞表现出协同抗肿瘤作用。
Zotero 插件